The use of biomarkers in detecting subclinical cardiotoxicity in doxorubicin-based treatment for paediatric patients with acute lymphoblastic leukaemia
Authors
Letiția Elena Radu
Paediatric Haematology and Oncology, Fundeni Clinical Institute,, Bucharest, Romania
Andra Beldiman
Fundeni Clinical Institute,, Bucharest, Romania
Ioana Ghiorghiu
“Carol Davila” University of Medicine and Pharmacy, Fundeni Clinical Institute, Bucharest, Romania
V. Gomoiu Children’s Hospital,, Bucharest, Romania
Alina Oprescu
Institute for Cardiovascular Diseases and Transplantation, Tirgu Mures, Romania
Constantin Arion
“Carol Davila” University of Medicine and Pharmacy, Fundeni Clinical Institute,, Bucharest, Romania
Anca Coliță
“Carol Davila” University of Medicine and Pharmacy, Fundeni Clinical Institute,, Bucharest, Romania
Language: English
Page range: 157 - 164
Submitted on: Jan 29, 2016
Accepted on: Apr 1, 2017
Published on: Apr 28, 2017
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2017 Letiția Elena Radu, Andra Beldiman, Ioana Ghiorghiu, Alina Oprescu, Constantin Arion, Anca Coliță, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.